openPR Logo
Press release

Creative Diagnostics Introduces the Launch of Beta Actin Antibody

03-04-2021 11:08 AM CET | Science & Education

Press release from: Creative Diagnostics

As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently expanded antibody portfolio with the launch of a series of beta actin antibody for ICC/IF, WB, and IHC-P. These new products are only for research use, and are not intended for diagnostic use.

Creative Diagnostics offers primary antibodies to multiple forms of virtually every protein in the proteome, and secondary antibodies that are available targeting all common research species and are conjugated with multiple types of enzymes and fluorescence, as well as control antibodies to make sure researchers generating data with confidence. Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. The anti beta actin monoclonal antibodies can be used to detect beta-actin, which is one of six different actin proteins.

For example, Anti-ACTB monoclonal antibody (DCABH-10282), one of the products included in this release, is mouse anti-Human ACTB monoclonal antibody that can be used for ICC/IF, WB, and IHC-P. This antibody can specifically recognize beta actin in tissues or species through immunoblotting, immunofluorescence staining of cultured cell lines, and immunohistochemistry.

"Creative Diagnostics is committed to developing and delivering high quality research tools and solutions to the life science community, and we're so glad to advance our clients' scientific discoveries and accelerate their next breakthrough by continuously offering such monoclonal antibodies. Our mouse monoclonal antibody to beta actin is now available for global researchers, and more improved antibodies and services will be offered to meet the unmet needs of scientists working in basic research and development." said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.

"Creative diagnostics offers a wide range of high quality antibodies validated for use in multiplexed assays. Beta actin antibodies are highly complementary to our existing antibody offerings and will further help us meet the continuing demands from our customers for high quality antibodies. We'll continue to work to develop more antibody products and customized services for researchers in the future." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.

If you want to know more information about beta actin antibodies or other research materials, please visit Creative Diagnostics at

NY 11967, USA

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Diagnostics Introduces the Launch of Beta Actin Antibody here

News-ID: 2251851 • Views: 312

More Releases from Creative Diagnostics

Creative Diagnostics Broadens Its Portfolio with New Pseudotyped GFP HPV
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently introduces new Pseudotyped GFP HPV for immunogenicity assessment in vaccine trials. This new series of HPV reporter virus particles can be used for measuring neutralizing anti-HPV antibodies in pseudovirion-based neutralization assays. Human papillomaviruses (HPVs) are double-stranded non-enveloped DNA viruses that infect keratinocytes of stratified squamous epithelia. Immunogenicity assessments in vaccine trials have focused
Creative Diagnostics Launches Fluorescently Labeled Gold Nanoparticles for Cellu …
With years of experience in the pharmaceutical and life science sector, Creative Diagnostics introduces a series of fluorescently labeled gold nanoparticles for efficient cell uptake, such as DiagNano™ Fluorophore Labeled Gold Nanoparticles, 10 nm, Cellular Uptake(GFL-10-CU), and DiagNano™ Fluorophore Labeled Gold Nanoparticles, 50 nm, Cellular Uptake (GFL-50-CU). These new products can be potentially used for cancer diagnostics, studies, and immunoassays. Colloidal and intracellular gold nanoparticles can be validated by confocal microscopy.
Creative Diagnostics Supports COVID-19 Testing with Antigen Lateral Flow Assay D …
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics now introduces COVID-19 Antigen Lateral Flow Assay Development, including the SARS-CoV-2 nucleoprotein antibody pair for rapid COVID-19 antigen assays to equip healthcare workers for rapid COVID-19 antigen detection. Additionally, Creative Diagnostics also offers SARS-CoV-2 antigen extraction buffer tubes that can be used as packing supplies for SARS-CoV-2 antigen extraction. The global COVID-19 pandemic has
ACE2 Products Are Available at Creative Diagnostics to Advance SARS-CoV-2 Resear …
With COVID-19 rapidly spreading globally, scientists all over the world are devoted to related researches, trying to find an effective vaccine or drug to stop this epidemic. Angiotensin-converting enzyme 2 (ACE2) is an integral membrane protein with considerable homologous to ACE, which belongs to the peptidase M2 family. In case of human coronaviruses SARS and HCoV-NL63 infections, ACE-2 serves as a functional receptor for the spike glycoprotein of both coronaviruses.

All 5 Releases

More Releases for R&D

High Performance Hovercraft Market - R&D Activities Opening New Opportunities
A hovercraft, also known as an air-cushion vehicle or ACV, is an amphibious craft capable of travelling over land, water, mud, ice, and other surfaces. In 2018, the market size of High Performance Hovercraft is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2018; while in China, the market size is valued at xx million US$ and will increase to
R&D Collaborative Projects by GD Rectifiers
GD Rectifiers have extensive experience in collaborative R&D projects and are proud to work with some of the UK’s pioneering power electronic companies to drive design and innovation forward. This R&D service helps drive GD Rectifiers forward as a cutting edge manufacturer embracing fundamental technologies that support product development that contribute to next generation products throughout: renewable energy, embedded systems, smart metrering and the rail industry. Power Assemblies, Controllers and
Transforming Pharmaceutical R&D with Data
ReportsWorldwide has announced the addition of a new report title Transforming Pharmaceutical R&D with Data to its growing collection of premium market research reports. Transforming Pharmaceutical R&D with Data In the current drug pricing environment, biopharmaceutical firms cannot afford to continue spending billions of dollars on development programs that are more than 90% likely to fail. Raising prices to compensate for expensive, risky research and development (R&D) is no longer an option
Noliac is expanding the R&D team
Noliac is looking for two new colleagues for the R&D team in Prague, Czech Republic: A Precision/Fine Mechanics and an Electroengineer. Precision/Fine Mechanics For the R&D team in Prague, Czech Republic, Noliac is looking for a Precision/Fine mechanics to work on modifying existing products and work with developing new. Noliac requires a colleague who: Is mechanically skilled with a focus on very small machinery. Holds a technical high school degree or an apprenticeship
Leiber GmbH further invests in R&D
Since February 2016, Leiber GmbH has been reinforced by Dr med vet Claudia Westfahl - a veterinarian specialized in animal nutrition - as part of the company's strategy to invest in new product developments. With the new position ‘Product Development Animal Nutrition’, Dr Westfahl is responsible for new product development in the field of functional feed ingredients for both pet as well as farm animals. After graduating at the University
Rising R&D Funding for Nanotechnology
Global nanotechnology market has been registering marked increase in funds allocation by the countries across the world, especially with new product development that received huge momentum due to these funding. An increase in global public funding for R&D initiatives supports quick commercialization of nano-based products. Fundings from governments, corporations, and venture capital exhibited a CAGR growth of 1% during 2008-2012. In future, it is expected that nanotechnology funding will grow